Ziaurrehman Tanoli

Ziaurrehman Tanoli

Auto-generated profile, based on publicly available information

Ziaurrehman Tanoli

Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki , Tukholmankatu 8, FI-00290 Helsinki

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2022 in Genomics, Proteomics & Bioinformatics
Verified
Journal Article
Open access
SZShuyu Zheng
Shuyu Zheng
WWWenyu Wang
Wenyu Wang
JAJehad Aldahdooh
Jehad Aldahdooh
AMAlina Malyutina
Alina Malyutina
TSTolou Shadbahr
Tolou Shadbahr
Jing TangJing Tang
Jing Tang
Combinatorial therapies have been recently proposed to improve the efficacy of anticancer treatment. The SynergyFinder R package is a software used to analyze pre-clinical drug combination datasets. Here, we report the major updates to the SynergyFinder R package for improved interpretation and annotation of drug combination screening results. Unlike the existing implementations, the updated SynergyFinder R package includes five main innovations. 1) We extend the mathematical models to higher-order drug combination data analysis and implement dimension reduction techniques for visualizing the synergy landscape. 2) We provide a statistical analysis of drug combination synergy and sensitivity with confidence intervals and P values. 3) We incorporate a synergy barometer to harmonize multiple synergy scoring methods to provide a consensus metric for synergy. 4) We evaluate drug combination synergy and sensitivity to provide an unbiased interpretation of the clinical potential. 5) We enable fast annotation of drugs and cell lines, including their chemical and target information. These annotations will improve the interpretation of the mechanisms of action of drug combinations. To facilitate the use of the R package within the drug discovery community, we also provide a web server at www.synergyfinderplus.org as a user-friendly interface to enable a more flexible and versatile analysis of drug combination data.

8 May 2019 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
BZBulat Zagidullin
Bulat Zagidullin
JAJehad Aldahdooh
Jehad Aldahdooh
SZShuyu Zheng
Shuyu Zheng
WWWenyu Wang
Wenyu Wang
YWYinyin Wang
Yinyin Wang
Jing TangJing Tang
Jing Tang
Drug combination therapy has the potential to enhance efficacy, reduce dose-dependent toxicity and prevent the emergence of drug resistance. However, discovery of synergistic and effective drug combinations has been a laborious and often serendipitous process. In recent years, identification of combination therapies has been accelerated due to the advances in high-throughput drug screening, but informatics approaches for systems-level data management and analysis are needed. To contribute toward this goal, we created an open-access data portal called DrugComb (https://drugcomb.fimm.fi) where the results of drug combination screening studies are accumulated, standardized and harmonized. Through the data portal, we provided a web server to analyze and visualize users’ own drug combination screening data. The users can also effectively participate a crowdsourcing data curation effect by depositing their data at DrugComb. To initiate the data repository, we collected 437 932 drug combinations tested on a variety of cancer cell lines. We showed that linear regression approaches, when considering chemical fingerprints as predictors, have the potential to achieve high accuracy of predicting the sensitivity of drug combinations. All the data and informatics tools are freely available in DrugComb to enable a more efficient utilization of data resources for future drug combination discovery.

14 February 2020 in Briefings in Bioinformatics
Verified
Journal Article
Open access
PDF file
ZTZiaurrehman Tanoli
Ziaurrehman Tanoli
USUmair Seemab
Umair Seemab
ASAndreas Scherer
Andreas Scherer
KWKrister Wennerberg
Krister Wennerberg
Jing TangJing Tang
Jing Tang
MVMarkus Vähä-Koskela
Markus Vähä-Koskela
Drug development involves a deep understanding of the mechanisms of action and possible side effects of each drug, and sometimes results in the identification of new and unexpected uses for drugs, termed as drug repurposing. Both in case of serendipitous observations and systematic mechanistic explorations, confirmation of new indications for a drug requires hypothesis building around relevant drug-related data, such as molecular targets involved, and patient and cellular responses. These datasets are available in public repositories, but apart from sifting through the sheer amount of data imposing computational bottleneck, a major challenge is the difficulty in selecting which databases to use from an increasingly large number of available databases. The database selection is made harder by the lack of an overview of the types of data offered in each database. In order to alleviate these problems and to guide the end user through the drug repurposing efforts, we provide here a survey of 102 of the most promising and drug-relevant databases reported to date. We summarize the target coverage and types of data available in each database and provide several examples of how multi-database exploration can facilitate drug repurposing.

18 March 2025 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
ZTZiaurrehman Tanoli
Ziaurrehman Tanoli
AFAdrià Fernández-Torras
Adrià Fernández-Torras
UÖUmut Onur Özcan
Umut Onur Özcan
AKAleksandr Kushnir
Aleksandr Kushnir
KNKristen Michelle Nader
Kristen Michelle Nader
TATero Aittokallio
Tero Aittokallio

3 June 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
ACAnna Cichońska
Anna Cichońska
BRBalaguru Ravikumar
Balaguru Ravikumar
RARobert Allaway
Robert Allaway
FWFangping Wan
Fangping Wan
SPSungjoon Park
Sungjoon Park
TATero Aittokallio
Tero Aittokallio
Despite decades of intensive search for compounds that modulate the activity of particular protein targets, a large proportion of the human kinome remains as yet undrugged. Effective approaches are therefore required to map the massive space of unexplored compound–kinase interactions for novel and potent activities. Here, we carry out a crowdsourced benchmarking of predictive algorithms for kinase inhibitor potencies across multiple kinase families tested on unpublished bioactivity data. We find the top-performing predictions are based on various models, including kernel learning, gradient boosting and deep learning, and their ensemble leads to a predictive accuracy exceeding that of single-dose kinase activity assays. We design experiments based on the model predictions and identify unexpected activities even for under-studied kinases, thereby accelerating experimental mapping efforts. The open-source prediction algorithms together with the bioactivities between 95 compounds and 295 kinases provide a resource for benchmarking prediction algorithms and for extending the druggable kinome.

1 January 2018 in Database: The Journal of Biological Databases and Curation
Verified
Journal Article
Open access
PDF file
ZTZiaurRehman Tanoli
ZiaurRehman Tanoli
ZAZaid Alam
Zaid Alam
MVMarkus Vähä-Koskela
Markus Vähä-Koskela
BRBalaguru Ravikumar
Balaguru Ravikumar
AMAlina Malyutina
Alina Malyutina
TATero Aittokallio
Tero Aittokallio
Drug Target Commons (DTC) is a web platform (database with user interface) for community-driven bioactivity data integration and standardization for comprehensive mapping, reuse and analysis of compound–target interaction profiles. End users can search, upload, edit, annotate and export expert-curated bioactivity data for further analysis, using an application programmable interface, database dump or tab-delimited text download options. To guide chemical biology and drug-repurposing applications, DTC version 2.0 includes updated clinical development information for the compounds and target gene–disease associations, as well as cancer-type indications for mutant protein targets, which are critical for precision oncology developments.